India Glycols Q3 FY26: Record Revenue & EBITDA, Debt Reduction
India Glycols reported record Q3 and 9M FY26 revenue and EBITDA. Q3 revenue rose 13% and EBITDA 36.1%. 9M revenue increased 11.4%, EBITDA 28.9%. Potable Spirits revenue grew 17% in 9M to ₹1,025 crore. The company achieved significant debt reduction of ₹582 crore and focused on high-margin chemicals and biofuels.
The announcement of record financial performance, significant debt reduction, and strong growth across multiple business segments is highly impactful for investors and stakeholders, indicating robust business health and positive future prospects.
The company reported record revenues and EBITDA, indicating strong operational and financial performance. Significant debt reduction and growth in key segments like Potable Spirits and Chemicals further contribute to a positive sentiment.
India Glycols Limited (IGL) announced a record revenue and EBITDA for both the third quarter (Q3) and the first nine months (9M) of FY26. The company reported a 13.0% year-on-year revenue growth and a 36.1% increase in EBITDA for Q3 FY26, with EBITDA margins at 16.0%. For 9M FY26, revenue grew by 11.4% and EBITDA by 28.9%, achieving a 15.0% EBITDA margin.
The Potable Spirits segment demonstrated strong performance with a 17% year-on-year net revenue growth for 9M FY26, totaling ₹1,025 crores, and sold 23.7 million cases, a 5% increase. The company is focusing on product innovation, premiumization, and regional expansion within this segment, including strengthening its partnership with Amrut.
In the Bio-based Specialty Chemicals and Performance Chemicals (BSPC) segment, EBITDA surged by 68% in Q3 and 26% for 9M FY26. This improvement is attributed to a focus on high-margin products and discontinuation of low-margin businesses, along with operational cost reductions. The company also reported a significant debt reduction of ₹582 crores, including ₹467 crores raised through preferential allotment and ₹116 crores paid in Q3 from internal accruals.
The Bio-Fuel segment saw a revenue increase of 45.2% in Q3 FY26 and 51.2% for 9M FY26, with corresponding EBIT growth of 273.2% and 108.5%, driven by India's ethanol blending program.
IGL is strategically positioning itself by focusing on bio-based ingredients and value-added segments, aiming for robust financial performance and continued growth.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.